ALEXANDRIA, Va., March 26 -- United States Patent no. 12,257,247, issued on March 25, was assigned to Monte Rosa Therapeutics AG (Basel, Switzerland).
"Targeted degradation of VAV1" was invented by Laura Ann McAllister (Basel, Switzerland), Andreas Ritzen (Basel, Switzerland) and Vladimiras Oleinikovas (Basel, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having an inflammatory or autoimmune disorder."
The patent was filed on April 11, 2024, under Appli...